Cargando…
Mitoquinone Helps Combat the Neurological, Cognitive, and Molecular Consequences of Open Head Traumatic Brain Injury at Chronic Time Point
Traumatic brain injury (TBI) is a heterogeneous disease in its origin, neuropathology, and prognosis, with no FDA-approved treatments. The pathology of TBI is complicated and not sufficiently understood, which is the reason why more than 30 clinical trials in the past three decades turned out unsucc...
Autores principales: | Haidar, Muhammad Ali, Shakkour, Zaynab, Barsa, Chloe, Tabet, Maha, Mekhjian, Sarin, Darwish, Hala, Goli, Mona, Shear, Deborah, Pandya, Jignesh D., Mechref, Yehia, El Khoury, Riyad, Wang, Kevin, Kobeissy, Firas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869514/ https://www.ncbi.nlm.nih.gov/pubmed/35203460 http://dx.doi.org/10.3390/biomedicines10020250 |
Ejemplares similares
-
Traumatic Brain Injury: Oxidative Stress and Novel Anti-Oxidants Such as Mitoquinone and Edaravone
por: Ismail, Helene, et al.
Publicado: (2020) -
MS-based glycomics: An analytical tool to assess nervous system diseases
por: Peng, Wenjing, et al.
Publicado: (2022) -
Glycomic and Glycoproteomic Techniques in Neurodegenerative Disorders and Neurotrauma: Towards Personalized Markers
por: Kobeissy, Firas, et al.
Publicado: (2022) -
LC-MS/MS-Based Proteomics Approach for the Identification of Candidate Serum Biomarkers in Patients with Narcolepsy Type 1
por: Sanni, Akeem, et al.
Publicado: (2023) -
Thorough overview of ubiquitin C‐terminal hydrolase‐L1 and glial fibrillary acidic protein as tandem biomarkers recently cleared by US Food and Drug Administration for the evaluation of intracranial injuries among patients with traumatic brain injury
por: Wang, Kevin K.W., et al.
Publicado: (2021)